-

FTRE INVESTOR ALERT: Kirby McInerney LLP Notifies Fortrea Holdings Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of the August 1, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ:FTRE) securities during the period of July 3, 2023, through February 28, 2025 (“the Class Period”).

[LEARN MORE ABOUT THE CLASS ACTION]

In March 2024, the Company announced that it was targeting 2025 adjusted EBITDA margins on a full-year basis of approximately 13%. In August 2024, the Company slightly lowered its targeted adjusted 2025 EBITDA margins to the “11% to 12% range,” but touted that this would still “represent a roughly 300 basis points improvement at the midpoint versus 2024, and broadly a 30% to 40% increase in adjusted EBITDA dollars delivered.”

On September 25, 2024, the investment bank Jefferies published a report (the “Jefferies Report”) downgrading Fortrea from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in Fortrea’s business model as a contract research organization amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are “not as material as [o]ne [m]ight think,” stating that “IT infrastructure costs to exit the TSAs are already non-GAAPed out of adjusted EBITDA. Thus, once TSAs are exited, Fortrea will just be replacing TSA costs with internal operating costs.” On this news, the price of Fortrea shares declined by $2.73 per share, from $22.21 per share on September 24, 2024, to close at $19.48 on September 25, 2025.

Then, on December 6, 2024, market analyst Baird Equity Research (“Baird”) downgraded Fortrea to neutral from outperform after the Company abruptly cancelled two scheduled conferences. A Baird analyst said that “given our ongoing concerns around the sector, Fortrea's choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell)[.]” On this news, the price of Fortrea shares declined by $1.90 per share from $23.57 per share on December 5, 2024, to close at $21.67 on December 6, 2024.

Finally, on March 3, 2025, Fortrea announced its fourth quarter and full year 2024 financial results, disclosing that its “targeted revenue and adjusted EBITDA trajectories for 2025 [were] not in line with [its] prior expectations.” Specifically, in an earnings call held that same day, Fortrea revealed that the Company’s Pre-Spin projects are “late in their life cycle [and] have less revenue and less profitability than expected for 2025” and that “post-spin work is not coming on fast enough to offset the pre-spin contract economics.” The Company also said this “older versus newer mix issue will continue to negatively impact Fortrea's financial performance during 2025.” On this news, the price of Fortrea shares declined by $3.47 per share, or approximately 25.1%, from $13.85 per share on February 28, 2025, to close at $10.38 on March 3, 2025.

The complaint filed alleges that defendants, throughout the Class Period, failed to disclose that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; and (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated.

If you purchased or otherwise acquired Fortrea securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you.

CONTACT FORM

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:FTRE

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

INVESTOR ALERT: Kirby McInerney LLP Files A Securities Class Action Lawsuit Against Camping World Holdings, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that it has filed a class action, Siverd v. Camping World Holdings, Inc. et al., No. 26 Civ. 2710, in the United States District Court for the Northern District of Illinois on behalf of investors who acquired Camping World Holdings, Inc. (“Camping World” or the “Company”) (NYSE:CWH) securities during the period of April 29, 2025 through February 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your Campi...

BYND DEADLINE NOTICE: Beyond Meat, Inc. Investors Encouraged to Contact Kirby McInerney LLP By March 24, 2026

NEW YORK--(BUSINESS WIRE)--If you suffered a loss on your investment in Beyond Meat, Inc. (“Beyond Meat” or the “Company”) (NASDAQ:BYND), contact Lauren Molinaro by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until March 24, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff o...

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual i...
Back to Newsroom